Dados B3 › FHER3 × GGBR4 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | FHER3 | GGBR4 | year |
|---|---|---|---|
| ROE | -192.0%! | 15.8% | 2023 |
| ROIC | -157.3%! | 15.6% | 2023 |
| ROA | -6.5% | 1.7% | 2025 |
| Gross margin | 0.2% | 11.4% | 2025 |
| EBIT margin | -6.5% | 5.4% | 2025 |
| Net margin | -4.2% | 2.0% | 2025 |
| Net debt/EBITDA | 0.54x | 0.31x | 2021 |
| Current ratio | 0.73x | 2.89x | 2025 |
| Revenue growth (1y) | -11.1% | 4.2% | 2025 |
| Revenue growth (5y CAGR) | 13.1% | 9.8% | 2025 |
| Piotroski F-Score | 4/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | FHER3 | GGBR4 | year |
|---|---|---|---|
| P/E | -1.25x | 30.77x | 2025 |
| P/B | — | 0.80x | 2025 |
| EV/EBITDA | — | 6.80x | 2025 |
| FCF yield | -33.1% | 2.7% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:02 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it